O-Chlorobutylabiraterone
✓
100% accuracy
of data
24/7 scientific
support
⬡
0% tolerance in
quality of product

Stock Locations

  • New Jersey, USA
  • Czech Republic, EU
  • Mumbai, India

* Stock subject to availability.

Documentation

Download MSDS

Download Sample COA

Includes: HPLC, MASS/LC-MS, 1H NMR, FT-IR, Potency, Structure Elucidation Report (SER), and additional analytical data depending on the product.

2484719-17-5O-Chlorobutylabiraterone

● Under Development

Catalogue No.:VL830019
CAS No.:2484719-17-5
Mol. Formula:C28H38ClNO
Mol. Weight:440.07 g/mol

Additional information on CAS 2484719-17-5

Parent drug

Abiraterone

IUPAC Name

3β-(4-Chlorobutoxyl)-17-(Pyridin-3-yl)androsta-5, 16-diene

Pharmacopoeial Synonyms

N/A

Other Synonyms

Chlorobutoxy Abiraterone;Pyridine, 3-(3-(4-chlorobutoxy)androsta-5,16-dien-17-yl)

Smiles

C[C@]12CC[C@@H](CC1=CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC=C4C5=CN=CC=C5)C)OCCCCCl

InChI

InChI=1S/C28H38ClNO/c1-27-13-11-22(31-17-4-3-15-29)18-21(27)7-8-23-25-10-9-24(20-6-5-16-30-19-20)28(25,2)14-12-26(23)27/h5-7,9,16,19,22-23,25-26H,3-4,8,10-15,17-18H2,1-2H3/t22-,23-,25-,26-,27-,28+/m0/s1

Description

O-Chlorobutylabiraterone is a meticulously characterized reference material that complies with rigorous regulatory requirements, including those defined by USP, EMA, JP, and BP. This product plays a crucial role in Abbreviated New Drug Applications (ANDA), New Drug Applications (NDA), and the commercial manufacturing of Abiraterone. It is further supported by a detailed Structure Elucidation Report (SER), ensuring high accuracy and reliability across a broad range of analytical applications. O-Chlorobutylabiraterone (CAS NO-2484719-17-5) is a steroidal compound with antiandrogen activity. Abiraterone is used to treat metastatic, castration-resistant prostate cancer mainly in patients who have undergone chemotherapy. Abiraterone acetate is a prodrug of abiraterone that blocks

References

Works Cited de Bono, Johann S., et al. “Abiraterone and Increased Survival in Metastatic Prostate Cancer.” New England Journal of Medicine, vol. 364, no. 21, 26 May 2011, pp. 1995–2005, 10.1056/nejmoa1014618.

Request a Quote

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
Products quotation
Name
Url